Jun 3 |
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
|
Jun 2 |
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
|
Jun 1 |
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
|
May 31 |
It's Unlikely That Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Will See A Huge Pay Rise This Year
|
May 26 |
Wall Street Breakfast: The Week Ahead
|
May 15 |
Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO
|
May 12 |
Arcus Biosciences, Inc. (NYSE:RCUS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
|
May 10 |
Arcus Biosciences Surpasses Analyst Revenue Forecasts in Q1 2024
|
May 10 |
Arcus Biosciences First Quarter 2024 Earnings: Beats Expectations
|
May 9 |
Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call Transcript
|